Cargando…

Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown cause characterised by progressive fibrotic formation in lung tissue. We hypothesise that disrupted metabolic pathways in IPF contribute to disease pathogenesis. METHODS: Metabolomics of human IPF was perform...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yidan D, Yin, Li, Archer, Stephen, Lu, Catherine, Zhao, George, Yao, Yan, Wu, Licun, Hsin, Michael, Waddell, Thomas K, Keshavjee, Shaf, Granton, John, de Perrot, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531310/
https://www.ncbi.nlm.nih.gov/pubmed/28883924
http://dx.doi.org/10.1136/bmjresp-2017-000183
_version_ 1783253355199463424
author Zhao, Yidan D
Yin, Li
Archer, Stephen
Lu, Catherine
Zhao, George
Yao, Yan
Wu, Licun
Hsin, Michael
Waddell, Thomas K
Keshavjee, Shaf
Granton, John
de Perrot, Marc
author_facet Zhao, Yidan D
Yin, Li
Archer, Stephen
Lu, Catherine
Zhao, George
Yao, Yan
Wu, Licun
Hsin, Michael
Waddell, Thomas K
Keshavjee, Shaf
Granton, John
de Perrot, Marc
author_sort Zhao, Yidan D
collection PubMed
description INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown cause characterised by progressive fibrotic formation in lung tissue. We hypothesise that disrupted metabolic pathways in IPF contribute to disease pathogenesis. METHODS: Metabolomics of human IPF was performed using mass spectroscopy (IPF lung=8; donor lung=8). Gene expression of key metabolic enzymes was measured using microarrays. Of the 108 metabolites whose levels were found altered, 48 were significantly increased, whereas 60 were significantly decreased in IPF samples compared with normal controls. RESULTS: Specific metabolic pathways mediating the IPF remodelling were found with a downregulated sphingolipid metabolic pathway but an upregulated arginine pathway in IPF. In addition, disrupted glycolysis, mitochondrial beta-oxidation and tricarboxylic acid cycle, altered bile acid, haem and glutamate/aspartate metabolism were found in IPF samples compared with control. CONCLUSIONS: Our results show alterations in metabolic pathways for energy consumption during lung structural remodelling, which may contribute to IPF pathogenesis. We believe that this is the first report of simultaneously and systemically measuring changes of metabolites involving nine metabolic pathways in human severe IPF lungs. The measurement of the metabolites may serve in the future diagnosis and prognosis of IPF.
format Online
Article
Text
id pubmed-5531310
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55313102017-09-07 Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study Zhao, Yidan D Yin, Li Archer, Stephen Lu, Catherine Zhao, George Yao, Yan Wu, Licun Hsin, Michael Waddell, Thomas K Keshavjee, Shaf Granton, John de Perrot, Marc BMJ Open Respir Res Interstitial Lung Disease INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown cause characterised by progressive fibrotic formation in lung tissue. We hypothesise that disrupted metabolic pathways in IPF contribute to disease pathogenesis. METHODS: Metabolomics of human IPF was performed using mass spectroscopy (IPF lung=8; donor lung=8). Gene expression of key metabolic enzymes was measured using microarrays. Of the 108 metabolites whose levels were found altered, 48 were significantly increased, whereas 60 were significantly decreased in IPF samples compared with normal controls. RESULTS: Specific metabolic pathways mediating the IPF remodelling were found with a downregulated sphingolipid metabolic pathway but an upregulated arginine pathway in IPF. In addition, disrupted glycolysis, mitochondrial beta-oxidation and tricarboxylic acid cycle, altered bile acid, haem and glutamate/aspartate metabolism were found in IPF samples compared with control. CONCLUSIONS: Our results show alterations in metabolic pathways for energy consumption during lung structural remodelling, which may contribute to IPF pathogenesis. We believe that this is the first report of simultaneously and systemically measuring changes of metabolites involving nine metabolic pathways in human severe IPF lungs. The measurement of the metabolites may serve in the future diagnosis and prognosis of IPF. BMJ Publishing Group 2017-06-05 /pmc/articles/PMC5531310/ /pubmed/28883924 http://dx.doi.org/10.1136/bmjresp-2017-000183 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Interstitial Lung Disease
Zhao, Yidan D
Yin, Li
Archer, Stephen
Lu, Catherine
Zhao, George
Yao, Yan
Wu, Licun
Hsin, Michael
Waddell, Thomas K
Keshavjee, Shaf
Granton, John
de Perrot, Marc
Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
title Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
title_full Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
title_fullStr Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
title_full_unstemmed Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
title_short Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
title_sort metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
topic Interstitial Lung Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531310/
https://www.ncbi.nlm.nih.gov/pubmed/28883924
http://dx.doi.org/10.1136/bmjresp-2017-000183
work_keys_str_mv AT zhaoyidand metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT yinli metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT archerstephen metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT lucatherine metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT zhaogeorge metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT yaoyan metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT wulicun metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT hsinmichael metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT waddellthomask metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT keshavjeeshaf metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT grantonjohn metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy
AT deperrotmarc metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy